Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

NSW Govt delivers foot-and-mouth vaccine to protect livestock

A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...

Scientists optimise delivery of mRNA to target cells

A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...

'Anti-reward' brain network helps explain cocaine addiction

A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...

Content from other channels on our network

[New Zealand] Transform from Security Awareness to a Security Culture: A Vital Shift for SMB Healthcare — Webinar

WA establishes $50m older hospitals maintenance fund

Clinical Safety in Digital Health — Introductory eLearning course launches

Victoria's first Chief Palliative Care Adviser to oversee framework refresh

NHS hospital pilots AI in discharge summaries

Biofoam box project provides eco seafood storage

Food and grocery sector records impressive growth

SA winery opts for bulk bag discharging

Legume storage heat costs farmers and processors

Foodmach partners with ACTIW Intralogistics

Rockwell appoints Applied Robotics as AMR partner

Carbon280 launches pilot plant for hydrogen storage technology

ARENA supports rail charging solution for heavy mining vehicles

Covalent Lithium achieves first product at Kwinana

Vic Government funding 11 manufacturers for defence supply chain